263 related articles for article (PubMed ID: 28084583)
1. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
Matsuo S; Watanabe J; Mitsuya K; Hayashi N; Nakasu Y; Hayashi M
Breast Cancer Res Treat; 2017 Feb; 162(1):169-179. PubMed ID: 28084583
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
Darlix A; Hirtz C; Thezenas S; Maceski A; Gabelle A; Lopez-Crapez E; De Forges H; Firmin N; Guiu S; Jacot W; Lehmann S
BMC Cancer; 2019 Jan; 19(1):110. PubMed ID: 30700265
[TBL] [Abstract][Full Text] [Related]
5. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer brain metastases - A 12 year review of treatment outcomes.
De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
[TBL] [Abstract][Full Text] [Related]
9. Cystic brain metastasis is associated with poor prognosis in patients with advanced breast cancer.
Sun B; Huang Z; Wu S; Ding L; Shen G; Cha L; Wang J; Song S
Oncotarget; 2016 Nov; 7(45):74006-74014. PubMed ID: 27659537
[TBL] [Abstract][Full Text] [Related]
10. The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation.
Lai SF; Chen YH; Liang TH; Hsu CY; Lien HC; Lu YS; Huang CS; Kuo SH
J Neurooncol; 2018 Jul; 138(3):637-647. PubMed ID: 29557535
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer subtypes and survival in patients with brain metastases.
Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
[TBL] [Abstract][Full Text] [Related]
13. Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.
Griguolo G; Dieci MV; Giarratano T; Giorgi CA; Orvieto E; Ghiotto C; Berti F; Della Puppa A; Falci C; Mioranza E; Tasca G; Milite N; Miglietta F; Scienza R; Conte P; Guarneri V
J Neurooncol; 2017 Jan; 131(2):369-376. PubMed ID: 27853958
[TBL] [Abstract][Full Text] [Related]
14. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
16. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
Cagney DN; Lamba N; Montoya S; Li P; Besse L; Martin AM; Brigell RH; Catalano PJ; Brown PD; Leone JP; Tanguturi SK; Haas-Kogan DA; Alexander BM; Lin NU; Aizer AA
Breast Cancer Res Treat; 2019 Jul; 176(1):171-179. PubMed ID: 30982195
[TBL] [Abstract][Full Text] [Related]
18. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype.
Matsunaga S; Shuto T; Kawahara N; Suenaga J; Inomori S; Fujino H
J Neurosurg; 2010 Dec; 113 Suppl():65-72. PubMed ID: 21121788
[TBL] [Abstract][Full Text] [Related]
19. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
20. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]